Are Analysts Bullish La Jolla Pharmaceutical Company (NASDAQ:LJPC) After Last Week?

May 18, 2018 - By Hazel Jackson

La Jolla Pharmaceutical Company (NASDAQ:LJPC) LogoInvestors sentiment decreased to 1 in 2017 Q4. Its down 0.61, from 1.61 in 2017Q3. It turned negative, as 19 investors sold La Jolla Pharmaceutical Company shares while 24 reduced holdings. 14 funds opened positions while 29 raised stakes. 24.34 million shares or 4.45% more from 23.31 million shares in 2017Q3 were reported.
Credit Suisse Ag owns 16,855 shares for 0% of their portfolio. Architects accumulated 70 shares. Moreover, Millennium Mngmt Limited Liability Co has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 9,214 shares. Rhumbline Advisers accumulated 0% or 16,090 shares. Amer Int Gru owns 11,778 shares or 0% of their US portfolio. Lpl Financial Lc holds 13,500 shares. Sectoral Asset Incorporated holds 854,301 shares. Schwab Charles Mgmt has 75,298 shares. Blackrock stated it has 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Gp One Trading L P has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). 19,800 are owned by Quantitative Mngmt Ltd Co. Advsr Asset Mngmt reported 14,684 shares. Stanley invested in 168,653 shares or 1.17% of the stock. Jennison Associates Limited Liability has 2.22M shares for 0.07% of their portfolio. Deutsche Fincl Bank Ag stated it has 39,318 shares.

Since December 29, 2017, it had 6 insider purchases, and 1 sale for $43.91 million activity. Another trade for 40,000 shares valued at $1.20 million was made by TANG KEVIN C on Friday, March 2. PERCEPTIVE ADVISORS LLC bought $1.62 million worth of stock or 50,000 shares. Douglass Laura L. had sold 10,000 shares worth $323,208.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Among 7 analysts covering La Jolla Pharmaceutical (NASDAQ:LJPC), 4 have Buy rating, 3 Sell and 0 Hold. Therefore 57% are positive. La Jolla Pharmaceutical had 10 analyst reports since December 8, 2017 according to SRatingsIntel. The rating was maintained by Cowen & Co on Friday, December 22 with “Buy”. Jefferies maintained La Jolla Pharmaceutical Company (NASDAQ:LJPC) rating on Friday, March 23. Jefferies has “Sell” rating and $2500 target. The rating was maintained by H.C. Wainwright on Tuesday, January 30 with “Buy”. The firm earned “Buy” rating on Friday, May 11 by Cowen & Co. The rating was downgraded by Jefferies on Monday, February 12 to “Underperform”. The stock has “Underweight” rating by JP Morgan on Friday, December 8. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Sell” rating given on Friday, December 8 by J.P. Morgan. Below is a list of La Jolla Pharmaceutical Company (NASDAQ:LJPC) latest ratings and price target changes.

11/05/2018 Broker: Cowen & Co Rating: Buy New Target: $50.0000 Maintain
23/03/2018 Broker: Jefferies Rating: Sell New Target: $25.0000 Maintain
12/02/2018 Broker: Jefferies Old Rating: Buy New Rating: Underperform Downgrade
30/01/2018 Broker: H.C. Wainwright Rating: Buy Maintain
22/12/2017 Broker: Cowen & Co Rating: Buy New Target: $55.0 Maintain
22/12/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $90.0
22/12/2017 Broker: SunTrust Rating: Buy
21/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $62 Initiates Coverage On
08/12/2017 Broker: J.P. Morgan Rating: Sell New Target: $20.0 Downgrade
08/12/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Underweight Old Target: $36 Downgrade

The stock decreased 0.33% or $0.11 during the last trading session, reaching $33.16. About 248,264 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has declined 16.89% since May 18, 2017 and is downtrending. It has underperformed by 28.44% the S&P500.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $867.28 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Another recent and important La Jolla Pharmaceutical Company (NASDAQ:LJPC) news was published by Nasdaq.com which published an article titled: “La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology …” on May 17, 2018.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.